|
'''Lumacaftor''' ('''VX-809''') is a pharmaceutical drug that acts as a ] during ] and increases the number of CFTR proteins that are trafficked to the cell surface.<ref name=2015revKuk/> It is available in a single pill with ]; the combination, ] (brand name ''Orkambi''), is used to treat people with ] who are homozygous for the ] mutation in the ] (CFTR) gene, the defective protein that causes the disease.<ref name=Label>. Last updated July 2015. Check index page for label updates</ref> It was developed by ] and the combination was approved by the FDA in 2015.<ref name=CW>{{cite web|title=Orkambi (lumacaftor and ivacaftor)|url=http://www.centerwatch.com/drug-information/fda-approved-drugs/drug/100082/orkambi-lumacaftor-and-ivacaftor|publisher=CenterWatch|accessdate=24 March 2016}}</ref> As of 2015, lumacaftor had no medical use on its own.<ref name=2015revKuk>{{cite journal | vauthors = Kuk K, Taylor-Cousar JL | title = Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects | journal = Therapeutic Advances in Respiratory Disease | volume = 9 | issue = 6 | pages = 313–26 | date = December 2015 | pmid = 26416827 | doi = 10.1177/1753465815601934 | doi-access = free }}</ref> |
|
'''Lumacaftor''' ('''VX-809''') is a pharmaceutical drug that acts as a ] during ] and increases the number of CFTR proteins that are trafficked to the cell surface.<ref name=2015revKuk/> It is available in a single pill with ]; the combination, ] (brand name ''Orkambi''), is used to treat people with ] who are homozygous for the ] mutation in the ] (CFTR) gene, the defective protein that causes the disease.<ref name=Label>. Last updated July 2015. Check index page for label updates</ref> It was developed by ] and the combination was approved by the FDA in 2015.<ref name=CW>{{cite web|title=Orkambi (lumacaftor and ivacaftor)|url=http://www.centerwatch.com/drug-information/fda-approved-drugs/drug/100082/orkambi-lumacaftor-and-ivacaftor|publisher=CenterWatch|accessdate=24 March 2016|archive-date=19 March 2016|archive-url=https://web.archive.org/web/20160319043353/http://www.centerwatch.com/drug-information/fda-approved-drugs/drug/100082/orkambi-lumacaftor-and-ivacaftor|url-status=dead}}</ref> As of 2015, lumacaftor had no medical use on its own.<ref name=2015revKuk>{{cite journal | vauthors = Kuk K, Taylor-Cousar JL | title = Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects | journal = Therapeutic Advances in Respiratory Disease | volume = 9 | issue = 6 | pages = 313–26 | date = December 2015 | pmid = 26416827 | doi = 10.1177/1753465815601934 | doi-access = free }}</ref> |
